PLRZ

Polyrizon Ltd

10.00

-0.01-0.10%

After Hours: 9.31 -0.69 -6.90%18:25 10/16 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE10.00/10.01

TODAY RANGE9.00-10.00

VOL19.38K

MARKET CAP24.29M

52 WEEK RANGE2.880-18.20

AVG VOL (3M)61.66K

% TURNOVER0.71%

TURNOVER--

P/E (TTM)-12.7081

% RANGE9.99%

EPS(TTM)-0.7869

P/E(FORWARD)--

P/B0.8707

BVPS11.49

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP23.97M

SHARES OUTSTANDING2.43M

NEXT EARNINGS--

FREE FLOAT2.40M

LOT SIZE1

EX-DATE11/28/2025

News

Press Releases

Financial Reports

Profile

TipRanks·10/05 20:27
Polyrizon Expands IP Moat With New U.S. Patent Filing for Intranasal Drug-Delivery Platform
TipRanks·09/28 20:58
Polyrizon Files First-Half 2026 Results Showing Higher Assets and Wider Loss
Seeking Alpha·09/28 20:26
Polyrizon Ltd. GAAP EPS of -$0.79
TipRanks·09/22 12:50
Polyrizon enrolls first patient in U.S. study of NASARIX
TipRanks·09/18 20:35
Polyrizon files to sell 404,166 ordinary shares for holders
TipRanks·09/04 14:57
Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement
NASDAQ·09/03 16:20
Polyrizon Announces $4 Mln Registered Direct Offering And Private Placement
Seeking Alpha·09/03 13:13
Polyrizon prices $4M registered direct offering
TipRanks·09/03 12:55
Polyrizon announces $4.0M registered direct offering
NASDAQ·09/02 14:35
Polyrizon Completes Clinical Site Contracting For NASARIX Trial; Advances Into FIH Study Execution
TipRanks·09/02 13:16
Polyrizon completes all five U.S. site contracts for Nasarix allergy study
TipRanks·08/20 20:28
Polyrizon Finalizes U.S. Clinical Site Network for NASARIX Allergy Study
NASDAQ·08/20 14:25
Polyrizon Finalizes U.S. Clinical Sites For NASARIX Allergy Study
TipRanks·08/20 13:35
Polyrizon completes clinical site network for NASARIX study
TipRanks·07/13 20:59
Polyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026

Same Industry

Name/Symbol

Change%

Price

Regeneron Pharmaceuticals

REGN

-1.27%

753.12

GRDX

BNTX

United Therapeutics Corp.

UTHR

+3.07%

549.16

Vertex Pharmaceuticals Inc

VRTX

+2.74%

498.50

Siga Technologie

SIGA

0.00%

3.280

Moderna

MRNA

+14.21%

225.00

CRL

Medpace Holdings

MEDP

+1.11%

616.63

TLPH

ICON plc

ICLR

+0.14%

164.40

CBPO

Iqvia Hldgs Inc

IQV

+0.92%

263.09

MOLECULAR PARTNERS AG

MOLN

+1.05%

3.850

Arcturus Therape

ARCT

+6.76%

13.74

Gilead Sciences Inc

GILD

+2.57%

151.72

PRAH

Incyte Corp

INCY

+0.04%

112.79

Aptevo Therapeutics Inc

APVO

-4.71%

1.620

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.